The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 36, Issue 2, 2005, Pages 362-369

  Tin, Ei Ei ^a   Bowonwatanuwong, Chureeratana ^b   Desakorn, Varunee ^a   Wilairatana, Polrat ^a   Krudsood, Srivicha ^a   Pitisuttithum, Punnee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Chon Buri Regional Hospital   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; AIDS RELATED COMPLEX; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ECONOMICS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PHYSICIAN; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; THAILAND; WEIGHT GAIN;

EID: 20444477505     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Anonymous. GPO-VIR, 2002: [Cited 2004 April]. Available from: URL: http//www.lists.essentials.org/pipermail/ip-health/2002March/002819.html
2. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J AIDS 2003; 33: 571-76.
3. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: update recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-91.
4. HAART: [Cited 2004 April]. Available from: URL: http//www.fhi.org/en/ TopicsAntiretroviralTherapy.htm
5. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-15.
6. Kaufmann GR, Bloch M, Zaunders JJ et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-69.
7. Lepri AC, Phillips AN, d'Ariminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS 2001; 15: 983-90.
8. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipodystrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J AIDS 2003; 32: 48-56.
9. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective study. Lancet 2001; 357: 592-98.
10. Munderi P, van Praag E, Vella S, et al. Principles of antiretroviral therapy (ART). In: Safe and effective use of antiretroviral treatments in adults with particular preferences to resource limited settings, 2000 [online]. [Cited 2004 April]. Available from: URL: http// www.whqlibdoc.who.int/hq/2000/ WHOHIS2000.04.pdf
11. Saint-Marc T, Partisani M, Poizont-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
12. Van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987-99.
13. UNAIDS/WHO. Epidemiological Fact Sheet, 2003. [Cited 2004 April]. Available from: URL: http//www.aids.org/FactSheets/411-guidelines.html
14. st ed. Philadelphia: Current Medicine; 1995: 1.8-1.9.